Novartis launches head on study with Galvus and oral diabetes pills
Friday, October 13, 2006 09:00 IST Basel
Novartis announced the start of Galiant, a significant clinical trial set to involve more than 7,500 people in the United States comparing the investigational oral type 2 diabetes medication Galvus (vildagliptin)
